Hypericin

Drug Profile

Hypericin

Alternative Names: SGX 301; VIMRxyn

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator New York University; Weizmann Institute of Science
  • Developer Soligenix
  • Class Anthraquinones; Anti-inflammatories; Antidepressants; Antipsoriatics; Antivirals; Cytostatics; Diagnostic agents; Perylenes; Polycyclic compounds; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Cell death stimulants; Photosensitisers; Singlet oxygen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cutaneous T cell lymphoma
  • Discontinued Glioma; Hepatitis C; HIV infections; Hyperhidrosis; Kaposi's sarcoma; Psoriasis

Most Recent Events

  • 22 Feb 2017 Soligenix receives patent allowance for Hypericin in European Union
  • 03 Feb 2017 The United Kingdom Medicines and Healthcare Products Regulatory Agency grants Promising Innovative Medicine designation for hypericin for the treatment of Cutaneous T-cell lymphoma
  • 11 Feb 2016 Discontinued - Phase-II for Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top